CARDIOVASCULAR DRUGS AND THERAPY, cilt.21, sa.6, ss.431-435, 2007 (SCI-Expanded)
Background Levosimendan is a relatively new cardiac inotropic agent with calcium sensitizing activity. This study was conducted to investigate the effects of levosimendan (L) and dobutamine (D) on renal function in patients hospitalized with decompensated heart failure (HF).